Work

Regional differences in overall survival (OS) in patients with advanced melanoma (MEL) who received nivolumab (NIVO) combined with ipilimumab (IPI) or NIVO alone in a phase 3 trial (CheckMate 067)

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx377.009

Authors: J.-J. Grob, D. Schadendorf, J. Wagstaff, I. Márquez-Rodas, C. Lebbé, P.A. Ascierto, F.S. Hodi, K. Grossmann, J.C. Hassel, D. Walker, R. Bhore, J. Larkin, J.D. Wolchok

Institutions: Hôpital de la Timone, Essen University Hospital, University of Duisburg-Essen, Singleton Hospital, Hospital General Universitario Gregorio Marañón, Inserm, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis, Université Paris Diderot, HIPI - Immunologie humaine, physiopathologie et immunithérapie, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Dana-Farber Cancer Institute, Huntsman Cancer Institute, Heidelberg University, University Hospital Heidelberg, National Center for Tumor Diseases, Bristol-Myers Squibb (United States), Royal Marsden Hospital, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Les Laboratories Pierre Fabre, Chugai Pharmaceutical

OpenAlex ID: W2762632678

FWCI: 0.916

Cites:

Cited by: 8

Related to: 10